Table 1.
Summary of TEAEs
| TEAE∗, n (%) | All patients (N = 158) |
|
|---|---|---|
| Any grade | Grade ≥3 | |
| Any TEAE | 155 (98) | 140 (89) |
| Neutropenia | 73 (46) | 67 (42) |
| Diarrhea | 70 (44) | 5 (3) |
| Nausea | 60 (38) | 2 (1) |
| Anemia | 43 (27) | 26 (16) |
| Fatigue | 43 (27) | 0 |
| Upper respiratory tract infection | 40 (25) | 2 (1) |
| Thrombocytopenia | 37 (23) | 25 (16) |
| Pneumonia | 35 (22) | 20 (13) |
| Cough | 30 (19) | 0 |
| Pyrexia | 30 (19) | 1 (1) |
| Headache | 28 (18) | 0 |
| Nasopharyngitis | 28 (18) | 0 |
| Malignant neoplasm progression | 25 (16) | 23 (15) |
| Urinary tract infection | 23 (15) | 3 (2) |
| Back pain | 21 (13) | 3 (2) |
| Vomiting | 21 (13) | 2 (1) |
| Arthralgia | 20 (13) | 2 (1) |
| Constipation | 20 (13) | 0 |
| Abdominal pain | 19 (12) | 5 (3) |
| Hypertension | 19 (12) | 9 (6) |
| Hypokalemia | 19 (12) | 4 (3) |
| Peripheral edema | 17 (11) | 4 (3) |
| Rash | 17 (11) | 1 (1) |
| Dyspnea | 16 (10) | 0 |
| Autoimmune hemolytic anemia | 12 (8) | 10 (6) |
| Leukopenia | 11 (7) | 8 (5) |
| Febrile neutropenia | 10 (6) | 10 (6) |
∗
Any-grade TEAEs reported in ≥10% of patients or grade ≥3 TEAEs reported in ≥5% of patients.